<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03647878</url>
  </required_header>
  <id_info>
    <org_study_id>A-DE-60000-009</org_study_id>
    <nct_id>NCT03647878</nct_id>
  </id_info>
  <brief_title>Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.</brief_title>
  <acronym>CABOCARE</acronym>
  <official_title>Prospective Non-interventional Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the protocol, is to describe the use of CabometyxTM (cabozantinib) tablets
      including the number of dose reductions, dose interruptions and terminations due to (serious)
      adverse events in subjects with advanced or metastatic renal cell carcinoma (mRCC) treated in
      real-life clinical setting in 1st line treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects with dose reduction due to Serious Adverse Events/Adverse Events (SAEs/AEs)</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of subjects with ≥1 dose reduction due to AE will be described with its 95% confidence interval, by risk group and overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with dose interruption due to SAEs/AEs</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of subjects with ≥1 dose interruption due to AE will be described with its 95% confidence interval, by risk group and overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion of subjects with termination of Cabozantinib due to SAEs/AEs</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of subjects with ≥1 discontinuation due to AE will be described with its 95% confidence interval, by risk group and overall.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Progression free survival is defined as the time between the start date of cabozantinib and the date of progression or death from any cause. Disease progression is defined as either radiological progression assessed by the investigator using RECIST 1.1 or clinical progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response - Overall Response Rate (ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>The best overall response is the best response assessed by investigator recorded during the treatment period. ORR is defined as the proportion of subjects achieving complete or partial response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response - Disease Control Rate (DCR)</measure>
    <time_frame>2 years</time_frame>
    <description>The best overall response is the best response assessed by investigator recorded during the treatment period. DCR is defined as the proportion of subjects achieving a complete response, partial response or stable disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All non-serious and serious adverse events (AEs / SAEs) and fatal outcomes</measure>
    <time_frame>2 years</time_frame>
    <description>Safety: clinical parameter, as routinely assessed by the investigator, as well as occurrence of all serious and non-serious AEs as well as fatal outcomes and special situations. The adverse events will be described overall and also according to level of physical activity assessed by questionnaire and actigraph.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the activity level at baseline on the occurrence of adverse events (AEs)</measure>
    <time_frame>2 years</time_frame>
    <description>Safety: clinical parameter, as routinely assessed by the investigator, as well as occurrence of all serious and non-serious AEs as well as fatal outcomes and special situations; data of activity level and quality of life will be collected using the quality of life questionnaire (NFKSI-19 questionnaire) and the activity questionnaire; inflammatory blood markers, as routinely assessed by the investigator, will be captured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with termination due to SAEs/AEs in sub-group</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of subjects with ≥1 termination due to AE will be described with its 95% confidence interval, by risk group and overall split by histological subtype (clear cell and non-clear cell).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with dose interruption due to SAEs/AEs in sub-group</measure>
    <time_frame>2 year</time_frame>
    <description>The proportion of subjects with ≥1 dose interruption due to AE will be described with its 95% confidence interval, by risk group and overall split by histological subtype (clear cell and non-clear cell).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with dose reduction due to SAEs/AEs in sub-group</measure>
    <time_frame>2 years</time_frame>
    <description>The proportion of subjects with ≥1 dose reduction due to AE will be described with its 95% confidence interval, by risk group and overall split by histological subtype (clear cell and non-clear cell).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Advanced or Metastatic Renal Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Cabozantinib in advanced or metastatic renal cell carcinoma in 1st
        line treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18 years and older with capacity to consent.

          -  Subjects receiving cabozantinib as a first line treatment for advanced or metastatic
             renal cell carcinoma

          -  Subjects with the intention to be treated with cabozantinib tablets according to the
             current local Summary of Product Characteristics (SmPC) (Germany, Austria); decision
             has to be taken before entry in the study.

          -  Signed written informed consent

        Exclusion Criteria:

          -  Participation in an interventional study at the same time and/or within 3 months
             before baseline.

          -  Previous participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Landeskrankenhaus Hochsteiermark</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salzkammergutklinikum Vöcklabruck</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>A-4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum am Bruderwald Medizinische Klinik V</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie</name>
      <address>
        <city>Berlin</city>
        <zip>12099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologie am Segelfliegerdamm</name>
      <address>
        <city>Berlin</city>
        <zip>12487</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>überörtl. Praxis für Urologie &amp; Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33615</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum für Operative Urologie</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edia.med MVZ</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologisches Zentrum Donauwörth</name>
      <address>
        <city>Donauwörth</city>
        <zip>86609</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden/Freiberg</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Georg Klinikum</name>
      <address>
        <city>Eisenach</city>
        <zip>99817</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitatmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologisches Studienzentrum am Raschplatz</name>
      <address>
        <city>Hannover</city>
        <zip>30161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Immunologisch onkologisches MVZ</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie, Onkologie und Gerinnung</name>
      <address>
        <city>Kronach</city>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Arztpraxis</name>
      <address>
        <city>Lutherstadt Eisleben</city>
        <zip>06295</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Urologie, Andrologie, Onkologie und medikamentöse Tumortherapie</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Gemeischaftspraxis Hochsauerland</name>
      <address>
        <city>Meschede</city>
        <zip>59872</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Moers</name>
      <address>
        <city>Moers</city>
        <zip>47441</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Facharztpraxis für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxis für Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Neustadt Am Rübenberge</city>
        <zip>31535</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ Kreis Olpe</name>
      <address>
        <city>Olpe</city>
        <zip>57462</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologische Praxis</name>
      <address>
        <city>Parchim</city>
        <zip>19370</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Elblandklinikum Riesa</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wissenschaftskontor Nord GmbH &amp;Co KG</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>MVZ MP Saaletal</name>
      <address>
        <city>Saalfeld/Saale</city>
        <zip>07318</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Sindelfingen-Böblingen</name>
      <address>
        <city>Sindelfingen</city>
        <zip>71065</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Studiengesellschaft Nord-West GmbH</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Praxisgemeinschaft für Onkologie und Urologie</name>
      <address>
        <city>Wilhelmshaven</city>
        <zip>26389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>GIM - Gemeinschaftspraxis Innere Medizin</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2018</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

